Moleculin Biotech Inc
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 po… Read more
Moleculin Biotech Inc (MBRX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.268x
Based on the latest financial reports, Moleculin Biotech Inc (MBRX) has a cash flow conversion efficiency ratio of 0.268x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.22 Million) by net assets ($-26.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Moleculin Biotech Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Moleculin Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Moleculin Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Moleculin Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Full Wang International Development Co Ltd
TWO:6219
|
-0.287x |
|
Powercom Co Ltd
TW:3043
|
0.008x |
|
Danakali Ltd
PINK:SBMSF
|
-0.005x |
|
Drb Industrial
KO:163560
|
-0.014x |
|
GREAT ELM GROUP NEW-001
F:PNC
|
N/A |
|
Optiscan Imaging Ltd
AU:OIL
|
-0.317x |
|
HBR Realty Empreendimentos Imobiliários S.A
SA:HBRE3
|
0.080x |
|
Defence Therapeutics Inc
OTCQB:DTCFF
|
0.512x |
Annual Cash Flow Conversion Efficiency for Moleculin Biotech Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Moleculin Biotech Inc from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $5.98 Million | $-23.86 Million | -3.991x | -331.75% |
| 2023-12-31 | $26.07 Million | $-24.10 Million | -0.924x | -74.55% |
| 2022-12-31 | $52.19 Million | $-27.64 Million | -0.530x | -120.74% |
| 2021-12-31 | $78.99 Million | $-18.95 Million | -0.240x | +75.85% |
| 2020-12-31 | $17.89 Million | $-17.77 Million | -0.993x | +10.06% |
| 2019-12-31 | $15.57 Million | $-17.20 Million | -1.104x | -29.18% |
| 2018-12-31 | $14.27 Million | $-12.20 Million | -0.855x | -99.84% |
| 2017-12-31 | $17.12 Million | $-7.32 Million | -0.428x | -70.01% |
| 2016-12-31 | $14.96 Million | $-3.76 Million | -0.252x | -144.25% |
| 2015-12-31 | $-744.70K | $-423.51K | 0.569x | -- |